Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C21H23F3O5S |
Molecular Weight | 444.465 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC=C(OCC(O)=O)C(C)=C2
InChI
InChIKey=JWHYSEDOYMYMNM-QGZVFWFLSA-N
InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1
Molecular Formula | C21H23F3O5S |
Molecular Weight | 444.465 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
MBX-8025 (Seladelpar) is an agonist of peroxisome proliferator-activated receptor delta. MBX-8025 improves insulin sensitivity and reverses dyslipidemia and hepatic storage of lipotoxic lipids to improve nonalcoholic steatohepatitis pathology in atherogenic diet-fed obese diabetic mice. MBX-8025 improves lipoprotein subfractions associated with atherogenic dyslipidemia. CymaBay Therapeutics is developing MBX-8025 for the treatment of patients with the autoimmune liver disease, primary biliary cholangitis and nonalcoholic steatohepatitis.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q03181|||Q9BUD4 Gene ID: 5467.0 Gene Symbol: PPARD Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/29404484 |
2.0 nM [EC50] |
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT02955602
Phase 2 study to evaluate the safety and efficacy of MBX-8025 2 mg, 5 mg, and 10 mg over 52 weeks of treatment
Route of Administration:
Oral
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 15:51:02 GMT 2023
by
admin
on
Fri Dec 15 15:51:02 GMT 2023
|
Record UNII |
7C00L34NB9
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
EU-Orphan Drug |
EU/3/17/1930
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Seladelpar
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
C167015
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
CHEMBL3545019
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
100000177208
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
DTXSID001045332
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
EF-45
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
7C00L34NB9
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
851528-79-5
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
10340
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
DB12390
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY | |||
|
11236126
Created by
admin on Fri Dec 15 15:51:02 GMT 2023 , Edited by admin on Fri Dec 15 15:51:02 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET->WEAK AGONIST |
EC50
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
SALT/SOLVATE -> PARENT | |||
|
TARGET -> AGONIST |
SELECTIVE
EC50
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |